Catalyst Watch

Stock TimeFrame Milestone
AMBS 10/6/2014 Unveil new Orphan indication at Targeting Ocular Disorders 2014 conference
AMBS 2014Q4 MANF Ocular Ischemic Syndrome Orphan Drug Designation Application
AMBS 2014Q4 MANF Retinitis Pigmentosa Orphan Drug Designation Application
AMBS 2014Q4 Uplist to Nasdaq
AMBS 2014Q4 MANF Pharmacology Data in Orphan Ocular Disease
AMBS MANF Drug Delivery Data in Parkinson’s disease
AMBS MANF Initiation of GMP Manufacturing
AMBS 2014Q4 LP-002 Data
AMBS 2014Q4 LP-002 Assay Validation at ICON
AMBS 2014Q4 LP-002 CLIA Submission
AMBS LP-002 Commercial Launch
ARIA 9/10/2014 Scientific Advisory Group meeting
ARIA 9/19/2014 Scientific Advisory Group meeting Comments
ARIA 9/26/2014 Updated Joint Rapporteurs’ assessment report circulated to PRAC and to CHMP:
ARIA Oct-14 Adoption of List of outstanding issues / PRAC recommendation to CHMP:
ARIA 2014Q4 Iclusig – EU PRAC protocol approval
ARIA 2015H1 Iclusig – France – approval and start recording revenue
ARIA 2015H1 Iclusig – Beligum – Promotional Launch
ARIA 2015H1 Iclusig – Sweden – Promotional Launch
ARIA 2015H1 Iclusig – Denmark – Promotional Launch
ARIA 2015H1 Iclusig – Finland – Promotional Launch
ARIA 2015H1 Iclusig – Ireland – Promotional Launch
ARIA 2015H1 Iclusig – Portugal – Promotional Launch
ARIA 2015H1 Iclusig – Spain – Promotional Launch
ARIA 2015H2 Iclusig – Isreal – Approval and Commercial Launch
ARIA 2015H2 Iclusig – Japan – progress toward approval and commercial launch
ARIA 2015Q1 Iclusig – Australia – Approval and Commercial Launch
ARIA 2015Q3 ALTA – Trial of 113 patients – Complete enrollment
ASTY 2014H2 AST-OPC1 Clinical Trial – FDA Clearance
ASTY 2014H2 AST-VAC2 Funding accouncement
ASTY 2014H2 Uplisting to Major Stock Exchange
ASTY 2015H1 AST-OPC1 Clinical Trial – Initiate
ASTY 2014Q3 AST-VAC2 UK Partnership announcement (Cancer Research Technology)
ASTY 2015H2 AST-VAC2 complete process transfer to UK Partner
ASTY 2015H2 AST-OPC1 30 day safety on 2m cell, dose escalation to 10m cell
ASTY 2016H1 AST-OPC1 10m cell 6 mos efficacy data
ASTY 2016H1 AST-VAC2 Clinical Trial – Initiate
CLDX 2014Q4 Varlilumab Clinical Trial – Initiate
CLDX 2014Q4 CDX-1401 Clinical Trial – Phase 1/2 by year end
CNAT 2015H2 emricasan Liver Cirrhosis – Complete
CNAT 2015Q3 emricasan portal hypertension   – Complete
CYNAF 2016Q3 NDA for APL-130277
NQ 2014Q3 20f filing by Nov 15th
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Advertisements

Sifting through the sludge, to find better investments.

%d bloggers like this: